Does using an Ommaya reservoir for intrathecal chemotherapy help leptomeningeal metastasis?

Leptomeningeal metastasis (LM) means cancer has spread into the fluid and membranes around the brain and spinal cord. It is a serious complication with poor survival, and doctors often treat it by putting chemotherapy drugs directly into the cerebrospinal fluid (CSF), the fluid that surrounds the brain and spine. This is called intrathecal chemotherapy. There are two main ways to deliver it: repeated lumbar puncture (a needle in the lower back) or an Ommaya reservoir, which is a small device implanted under the scalp that connects to the fluid spaces of the brain ³⁵. The short answer is that the Ommaya route is a well-established standard, and the best available comparison suggests it may give better disease control and longer survival than lumbar puncture, though the evidence has limits ³⁷.

What the research says

A 2026 systematic review and meta-analysis directly compared the two delivery routes in patients with LM. It pooled studies published from 1986 to 2026 and found that intrathecal chemotherapy given through an Ommaya reservoir was linked to better outcomes than repeated lumbar puncture, including disease control and overall survival ³⁷. That is the most direct evidence on your question, because it compares the routes head to head rather than just describing one.

Other reviews support the Ommaya reservoir as a practical and increasingly used route. A systematic review of LM from non-small cell lung cancer notes that the Ommaya reservoir is an implantable ventricular access device that achieves therapeutic drug levels in the CSF, and it has been used more and more in this setting ⁵⁸. A broader review of intrathecal therapy in lung cancer LM found that drug delivery was done by either lumbar puncture or Ommaya reservoir, with objective response rates ranging from 34.5% to 86.4% and disease control rates from 62.5% to 94.9% ². Those numbers mix both routes, so they show that intrathecal therapy can work, not that one route is always better.

Case reports show the reservoir working in specific cancers. In one report, a woman with cervical cancer and LM had an Ommaya reservoir placed and started intrathecal methotrexate. She had rapid neurological improvement, her CSF pressure normalized, and malignant cells cleared from her CSF on repeat testing, and she survived 8 months after the LM diagnosis ⁶. In another case, a man with pancreatic cancer that had spread to the lining of the brain had a shunt and Ommaya reservoir placed, then received intrathecal methotrexate with dexamethasone ¹. These are single cases, so they show what is possible but cannot prove the reservoir is better than other options.

A review of LM in EGFR-mutant lung cancer stresses that treatment decisions are multimodal, combining targeted therapies, intrathecal drug delivery, radiotherapy, and devices to relieve pressure. It notes that these combinations can improve neurological outcomes and survival for some patients, but that toxicity, unpredictable efficacy, and the logistics of coordinating care remain real obstacles ⁴. In short, the Ommaya reservoir is a recognized standard route, and the comparison data lean in its favor, but the evidence base is still mostly from pooled and observational studies rather than large randomized trials.

What to ask your doctor

• How does an Ommaya reservoir compare with repeated lumbar puncture for my specific cancer type and situation?
• What are the risks of placing and maintaining an Ommaya reservoir, such as infection or bleeding, versus the risks of repeated lumbar punctures?
• Which intrathecal drug or drug combination would you recommend for my cancer, and what response rates have been seen with it?
• How will we track whether the treatment is working, for example with CSF tests, MRI, or neurological exams?
• Should intrathecal therapy be combined with other treatments like targeted therapy or radiotherapy for my case?